| Literature DB >> 35778674 |
Britta C Arends1, Leon Timmerman2, Lisette M Vernooij1,3, Lisa Verwijmeren1, Douwe H Biesma4, Eric P A van Dongen1, Peter G Noordzij1, Heleen J Blussé van Oud-Alblas1.
Abstract
BACKGROUND: Chronic pain after cardiac surgery, whether or not related to the operation, is common and has negative impact on health related quality of life (HRQL). Frailty is a risk factor for adverse surgical outcomes, but its relationship with chronic pain after cardiac surgery is unknown. This study aimed to address the association between frailty and chronic pain following cardiac surgery.Entities:
Keywords: Chronic pain; Elderly; Frailty; Postoperative pain
Mesh:
Year: 2022 PMID: 35778674 PMCID: PMC9248159 DOI: 10.1186/s12871-022-01746-x
Source DB: PubMed Journal: BMC Anesthesiol ISSN: 1471-2253 Impact factor: 2.376
Fig. 1Pain intensity before and one year after cardiac surgery. n: Number
Baseline patients characteristics
| Male sex | 240 (71) | 109 (60) | 0.01 |
| Age, years | 74 (72 – 77) | 75 (72 – 78) | 0.09 |
| BMI (kg∙m−2) | 26.20 (24.20 – 28.70) | 26.60 (24.42 – 30.10) | 0.16 |
| EuroSCORE II | 1.69 (1.21 – 2.91) | 2.16 (1.39 – 3.66) | 0.001 |
| Preoperative use of analgesics | |||
| Acetaminophen | 19 (6) | 15 (8) | 0.34 |
| NSAIDs | 12 (4) | 11 (6) | 0.28 |
| Opioids | 9 (3) | 12 (7) | 0.05 |
| Antidepressants | 14 (4) | 16 (9) | 0.05 |
| Type of surgery | |||
| Single CABG or maze | 124 (37) | 55 (30) | 0.15 |
| Single valve | 91 (27) | 53 (29) | 0.70 |
| Combined surgery | 97 (29) | 59 (32) | 0.46 |
| Aortic surgery | 24 (7) | 15 (8) | 0.78 |
| Duration of surgery, minutes | 204 (163 – 250) | 210 (168 – 258) | 0.50 |
| Remifentanyl (microgram) | 2000 (1502 – 2000) | 2000 (1079 – 2000) | 0.004 |
| Use of internal mammary artery | 166 (49) | 72 (40) | 0.04 |
| Length of stay in the ICU, days | 1 (1 – 2) | 1 (1 – 3) | 0.04 |
| Length of hospital stay, days | 8 (7 – 12) | 9 (7 – 15) | 0.07 |
| Complication (re-thoracotomy) | 15 (5) | 13 (7) | 0.28 |
| Living alone | 57 (18) | 53 (29) | < 0.01 |
| Lower education | 77 (23) | 53 (29) | 0.15 |
| Polypharmacy | 211 (63) | 134 (74) | 0.02 |
| Excessive polypharmacy | 42 (13) | 46 (25) | < 0.001 |
| MMSE, points | 29 (28 – 30) | 29 (27 – 30) | 0.37 |
| 5 Meter walk test, seconds | 4.6 (4.1 – 5.3) | 4.9 (4.2 – 5.9) | < 0.001 |
| Timed get up and go test, seconds | 9.7 (8.5 – 11.2) | 10.4 (8.7 – 12.8) | 0.002 |
| Low grip strength | 118 (35) | 71 (39) | 0.45 |
| Nagi’s scale, points | 0 (0 – 1) | 1 (0 – 2) | < 0.001 |
| MNA, points | 13 (12 – 14) | 12.5 (11 – 14) | 0.06 |
| Mental HRQL, points | 53.1 (44.1 – 58.0) | 47.9 (37.7 – 54.0) | < 0.001 |
| Physical HRQL, points | 44.6 (35.7 – 52.0) | 41.0 (32.1 – 49.3) | 0.005 |
Continuous values as mean (± standard deviation) or median (1st to 3rd quartile), categorical values as frequency (%). n number, BMI Body mass index, NSAIDs Non-steroid anti-inflammatory drugs, CABG Coronary artery bypass grafting, ICU Intensive care unit, MMSE Minimal mental state examination, MNA Mini-nutritional assessment, HRQL Health related quality of life
Fig. 2Adjusted relative risks for the development of chronic pain. aRR Adjusted relative risk, CI Confidence interval, MMSE Minimal mental state examination, MNA Mini-nutritional assessment, HRQL Health related quality of life. Polypharmacy was added as factor with polypharmacy defined as ≥ 5 and < 10 prescriptions and excessive polypharmacy defined as ≥ 10 prescriptions used. No polypharmacy was used as reference category. Log-binomial regression was used for statistical testing with correction for EuroSCORE II, intraoperative use of remifentanil, preexisting chronic pain and use of internal mammary artery. P-value ≤ 0.01 was considered statistically significant. #; per point decrease on physical and mental HRQL
Fig. 3Change in health related quality of life in eight sub-scores.*p < 0.01, tested with Wilcoxon signed-rank test